Why AbbVie Shares Appear to Be an Exceptionally Bargain Purchase at This Moment

AbbVie: A Healthcare Leader Facing Market Challenges

AbbVie (NYSE: ABBV) is recognized as a leading company in the healthcare sector, yet its recent stock performance has lagged. Shares have dropped 11% this year, trailing the S&P 500, which is down just 4%. The broader healthcare industry has also struggled, with the Healthcare Select Sector SPDR ETF declining by 6%. Ongoing worries about healthcare policy changes and potential government spending cuts have contributed to this negative sentiment.

Despite these headwinds, investors may find now to be a strategic moment to consider AbbVie. The company’s recent struggles do not necessarily diminish its long-term potential. Here’s why AbbVie could be an overlooked opportunity for those seeking value in the current market.

AbbVie’s Resilience and Growth Drivers

AbbVie has faced significant challenges in recent years, including disruptions from the pandemic and the loss of patent exclusivity for its flagship drug, Humira. Nevertheless, the company has demonstrated adaptability, with new immunology treatments like Skyrizi and Rinvoq stepping in to fill the gap. Last year, these two medications generated $25.9 billion in sales, while Humira’s revenue dropped to $4.5 billion—half of its previous total.

In 2025, AbbVie reported total revenue of $61.2 billion, marking a 9% increase from the prior year. The company’s growth has been gaining momentum, as reflected in recent quarterly results.

AbbVie’s broad portfolio provides multiple avenues for expansion. While its core business performed well, sales in its aesthetics division declined by 6%. However, this area could rebound as consumer spending strengthens, offering additional growth potential.

AbbVie Shares Offer Attractive Value

Even if AbbVie’s growth moderates, the stock appears attractively priced. Currently, it trades at a forward price-to-earnings ratio of just 14, significantly lower than the S&P 500 average of 21.

The company’s price-to-earnings-growth (PEG) ratio stands at 0.49, indicating that the stock is undervalued relative to its expected earnings growth over the next five years. A PEG below 1.0 is generally considered a bargain, and the lower the number, the better the value proposition.

While AbbVie may not be the most exciting pick at the moment, it offers substantial long-term upside. With a dividend yield of 3.4%, investors have a compelling reason to consider holding AbbVie for the future.

Is Now the Time to Invest in AbbVie?

Before making a decision on AbbVie, consider this:

• The Motley Fool Stock Advisor team recently identified their top 10 stocks to buy now—and AbbVie was not among them. The selected companies could deliver significant returns in the years ahead.
• For example, when Netflix was recommended on December 17, 2004, a $1,000 investment would now be worth $495,179. Similarly, a $1,000 investment in Nvidia from April 15, 2005, would have grown to $1,058,743.
• Currently, Stock Advisor boasts an average total return of 898%, far outpacing the S&P 500’s 183%. Don’t miss the latest top 10 picks, available with Stock Advisor, and join a community designed for individual investors.

*Stock Advisor returns as of March 23, 2026.

David Jagielski, CPA does not hold positions in any of the stocks discussed. The Motley Fool owns shares of and recommends AbbVie. For more information, see The Motley Fool’s disclosure policy.